American Century Companies Inc. Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

American Century Companies Inc. lifted its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 181.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,310 shares of the company’s stock after purchasing an additional 38,261 shares during the quarter. American Century Companies Inc.’s holdings in Amylyx Pharmaceuticals were worth $224,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Blue Trust Inc. raised its position in Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after acquiring an additional 4,883 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth $56,000. Barclays PLC increased its holdings in shares of Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after purchasing an additional 40,319 shares in the last quarter. Kennondale Capital Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $508,000. Finally, JPMorgan Chase & Co. boosted its holdings in Amylyx Pharmaceuticals by 144.4% during the third quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock worth $455,000 after buying an additional 83,048 shares in the last quarter. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Trading Up 6.8 %

NASDAQ:AMLX opened at $3.90 on Tuesday. The company has a market capitalization of $345.55 million, a P/E ratio of -1.02 and a beta of -0.53. The firm has a 50-day moving average price of $3.54 and a two-hundred day moving average price of $4.09. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. On average, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AMLX. Mizuho raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the company from $3.00 to $7.00 in a report on Monday, April 7th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 11,851 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $3.47, for a total value of $41,122.97. Following the transaction, the chief executive officer now directly owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. This represents a 0.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Frates sold 10,896 shares of the firm’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the sale, the chief financial officer now directly owns 290,988 shares in the company, valued at $1,009,728.36. This represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,509 shares of company stock valued at $222,586. Corporate insiders own 11.70% of the company’s stock.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.